Keywords: Prostate, Prostate, Hyperpolarized 13C MRI
Motivation: Hyperpolarized (HP) 13C-pyruvate MRI can address limitations of PSMA-PET for monitoring therapy and evaluating treatment-emergent, lethal subtypes of prostate cancer.
Goal(s): To establish and characterize a novel radiomics framework of tumor metabolism in advanced prostate cancer based on whole abdominopelvic HP MRI.
Approach: We extracted 316 metabolic features from 16 patients. Following feature selection and classification, their prognostic values were evaluated using uni- and multivariate survival analyses.
Results: Metabolic feature kPL,median (pyruvate-to-lactate conversion rate) significantly predicted both progression-free (p<0.01) and overall (p<0.05) survivals with longer median PFS (11.2 vs 0.5 months) and OS (NR vs 18.4 months) in the lower- vs higher-kPL subgroups.
Impact: A novel radiomics framework based on whole abdominopelvic hyperpolarized 13C-pyruvate MRI extracted and evaluated 316 metabolic features of advanced prostate cancer. Selected features significantly predicted clinical outcome measures (PFS and OS), strongly supporting further investigation of their prognostic values.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords